局部递送靶向疗法领导者，普祺医药能否撑起24亿估值？

Core Viewpoint - Beijing Puxi Pharmaceutical Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to raise funds due to its urgent financial situation and lack of product revenue [1][2]. Company Overview - Puxi Pharmaceutical focuses on the field of immune inflammation, positioning itself as a leader in localized delivery targeted therapies [1]. - The company was established in 2016 and has developed a core technology platform centered on innovative design and localized delivery [1]. - As of September 2025, the company reported cash and cash equivalents of only 155 million RMB, highlighting its urgent need for financing through the IPO [1]. Product Pipeline - The core product, PG-011 (Pumexitinib), is a JAK1/JAK2 inhibitor designed for external use, with formulations in gel and nasal spray currently in late-stage clinical trials [2][3]. - Pumexitinib gel is the first JAK inhibitor gel globally for treating atopic dermatitis, having completed Phase III trials for adults and adolescents aged 12 to 17 [2]. - The nasal spray formulation is the first clinical-stage JAK inhibitor for treating seasonal allergic rhinitis, currently in Phase III trials for adults [3]. Market Potential - The global autoimmune disease drug market is projected to grow from $116.9 billion in 2019 to $143.1 billion by 2024, with a compound annual growth rate (CAGR) of 4.1% [4]. - The Chinese autoimmune disease drug market is expected to expand from 16.2 billion RMB in 2019 to 32.8 billion RMB by 2024, with a much higher CAGR of 15.1% [6]. Competitive Landscape - The JAK inhibitor market is highly competitive, with multiple oral JAK1 inhibitors already approved in China for treating moderate to severe atopic dermatitis [8]. - Puxi Pharmaceutical faces significant challenges as a latecomer in a crowded market, needing to establish differentiation in efficacy, safety, or compliance [8]. Commercialization Strategy - The company has signed an exclusive commercialization agreement with Jichuan Pharmaceutical for Pumexitinib nasal spray in China, receiving up to 100 million RMB in payment [12]. - The success of Puxi Pharmaceutical's products will heavily depend on the approval timelines and outcomes of negotiations with health insurance for pricing [10][12].